These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 27913299)

  • 1. The inhibitory effect of beta-lapachone on RANKL-induced osteoclastogenesis.
    Gu DR; Lee JN; Oh GS; Kim HJ; Kim MS; Lee SH
    Biochem Biophys Res Commun; 2017 Jan; 482(4):1073-1079. PubMed ID: 27913299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling.
    Park KH; Gu DR; Jin SH; Yoon CS; Ko W; Kim YC; Lee SH
    Am J Chin Med; 2017; 45(8):1725-1744. PubMed ID: 29121799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytosolic malate dehydrogenase regulates RANKL-mediated osteoclastogenesis via AMPK/c-Fos/NFATc1 signaling.
    Oh SJ; Gu DR; Jin SH; Park KH; Lee SH
    Biochem Biophys Res Commun; 2016 Jun; 475(1):125-32. PubMed ID: 27179783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteon Myospalacem Baileyi attenuates osteoclast differentiation through RANKL induced NFAT pathways.
    Cui Y; Zhao X; Mei L; Pei J; Wang S; Shao Y; Tao Y; Zhang X; Jiang L
    J Ethnopharmacol; 2018 Mar; 213():65-71. PubMed ID: 29107144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helvolic acid attenuates osteoclast formation and function via suppressing RANKL-induced NFATc1 activation.
    Chen K; Yuan Y; Wang Z; Song D; Zhao J; Cao Z; Chen J; Guo Q; Chen L; Tickner J; Xu J
    J Cell Physiol; 2019 May; 234(5):6477-6488. PubMed ID: 30341897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
    Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
    Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression.
    Han SY; Kim YK
    Am J Chin Med; 2019; 47(2):439-455. PubMed ID: 30827151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
    Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Esculetin attenuates receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation through c-Fos/nuclear factor of activated T-cells c1 signaling pathway.
    Baek JM; Park SH; Cheon YH; Ahn SJ; Lee MS; Oh J; Kim JY
    Biochem Biophys Res Commun; 2015 May; 461(2):334-41. PubMed ID: 25887803
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Rattajak P; Aroonkesorn A; Smythe C; Wititsuwannakul R; Pitakpornpreecha T
    Molecules; 2024 May; 29(9):. PubMed ID: 38731604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Euphorbia factor L1 inhibits osteoclastogenesis by regulating cellular redox status and induces Fas-mediated apoptosis in osteoclast.
    Hong SE; Lee J; Seo DH; In Lee H; Ri Park D; Lee GR; Jo YJ; Kim N; Kwon M; Shon H; Kyoung Seo E; Kim HS; Young Lee S; Jeong W
    Free Radic Biol Med; 2017 Nov; 112():191-199. PubMed ID: 28774817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nrf2 deficiency induces oxidative stress and promotes RANKL-induced osteoclast differentiation.
    Hyeon S; Lee H; Yang Y; Jeong W
    Free Radic Biol Med; 2013 Dec; 65():789-799. PubMed ID: 23954472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unkeito Suppresses RANKL-Mediated Osteoclastogenesis via the Blimp1-Bcl6 and NF-κB Signaling Pathways and Enhancing Osteoclast Apoptosis.
    Fang K; Murakami Y; Kanda S; Shimono T; Dang AT; Ono M; Nishiyama T
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
    Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
    Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
    Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
    Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
    Xu H; Chen F; Liu T; Xu J; Li J; Jiang L; Wang X; Sheng J
    Chem Biol Interact; 2020 Nov; 331():109235. PubMed ID: 32971123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sappanone A inhibits RANKL-induced osteoclastogenesis in BMMs and prevents inflammation-mediated bone loss.
    Choo YY; Tran PT; Min BS; Kim O; Nguyen HD; Kwon SH; Lee JH
    Int Immunopharmacol; 2017 Nov; 52():230-237. PubMed ID: 28946117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.